Phase 2b DME Trial Completes Enrollment
A phase 2b trial assessing the safety and efficacy of ALG-1001 (Luminate, Allegro) as DME therapy has completed enrollment. The company expects to report top-line data by the third quarter of 2016.
DEL MAR is a double-masked, placebo-controlled, multicenter 6-month phase 2b trial evaluating the safety and efficacy of intravitreal ALG-1001 compared with bevacizumab (Avastin, Genentech) in patients with DME. In the trial, 120 patients will be randomly assigned to receive one of three doses of ALG-1001 (1.0 mg, 2.0 mg, or 3.0 mg) or bevacizumab.